The TATA box-binding protein (TBP) interacts in vitro with the activation domains of many viral and cellular transcription factors and has been proposed to be a direct target for transcriptional activators. We have examined the functional relevance of activator-TBP association in vitro to transcriptional activation in vivo. We (10) (11) (12) (13) (14) 20) , and a mutation in yeast TBP that disrupts activation domain binding also disrupts activation of transcription in vitro (21). However, the in vivo effects of mutations in TBP that block interaction with activation domains have not been described.
activation domain can also tightly associate with TBP in vitro, but fails to activate transcription in vivo. These data suggest that the ability of TBP to interact with activation domains in vitro is not directly relevant to its ability to support activated transcription in vivo.
RNA polymerase II transcription in eukaryotes is controlled by a diverse range of regulatory proteins that signal the conserved basal transcriptional machinery to initiate transcription. Transcriptional activators are proposed to function by directly contacting one or more of the basal factors (reviewed in ref. 1) , enhancing the rate of basal factor recruitment to the promoter (2) (3) (4) or the rate of promoter clearance and elongation (5) . Although transcriptional activation has been studied extensively in vitro, little is known of the way in which the basal factors respond to activators in vivo.
We have previously studied the role played by the TATA box-binding protein (TBP)-a central component of the basal transcription factor TFIID-in transcriptional response to a wide range of activators in human cells (6) . We found that TBP activity in vivo is resistant to single sets of mutations on the surface of the molecule but is sensitive to specific combinations of mutations in different regions across the protein. This pattern of behavior correlates well with the ability of TBP to associate with the largest TBP-associated factor (TAF) in the TFIID complex, hTAF11250, suggesting that recruitment of TBP into TFIID plays a major role in transcriptional activation in vivo.
Despite the importance of TFIID, however, activators may have multiple targets among the basal machinery (1), including TFIIB (3, 7, 8) and TBP itself. Indeed, the acidic activation domain of the herpes simplex virus transactivator VP16 (9) , as well as the activation (refs. 1 and 10-15 and refs. therein) or DNA-binding (16) (17) (18) (19) domains of at least 25 other transcriptional activators associate directly with TBP in vitro. Furthermore, mutational analyses of activation domains have revealed a good correlation between the ability of activators to associate with TBP and to activate transcription both in vitro and in vivo (10) (11) (12) (13) (14) 20) , and a mutation in yeast TBP that disrupts activation domain binding also disrupts activation of transcription in vitro (21) . However, the in vivo effects of mutations in TBP that block interaction with activation domains have not been described.
Here we analyze the relationship between transcription factor-TBP association in vitro and transcriptional activation in vivo. We demonstrate that both the VP16 transcriptional activation domain and the remainder of the protein associate with TBP in vitro, but only the activation domain activates transcription in vivo. We also show that point mutations in a loop connecting a-strands S3' and S4' of human TBP disrupt association with the VP16 and p53 activation domains in vitro, but they do not affect transcriptional activation in vivo. We conclude that the ability of TBP to associate with activation domains in vitro is neither necessary nor sufficient for transcriptional activation in vivo.
MATERIALS AND METHODS
Plasmid DNA Manipulations. Mutant TBP constructs were derived by site-directed mutagenesis (22) of the parental pCGN construct encoding altered-specificity human TBP (6), designated TBPAS. GAL4-fusion proteins were constructed by insertion of the appropriate fragments into the Xba I and BamHI sites of the vector pCGGAL(1-94) (23) , provided by C. Hinkley (Cold Spring Harbor Laboratory). pCGGAL(1-94)-p53AD was constructed by PCR amplification of sequences encoding residues 1-73 of human p53 from the vector pBS-p53 (gift of C. Prives, Columbia University, New York) and insertion of the resulting fragment into pCGGAL For production of recombinant glutathione-S-transferase (GST)-fusion proteins in Escherichia coli, Xba I/BamHI fragments encoding the activation domains of p53 (residues 1-73) and VP16 (residues 413-490) were inserted into the Xba I and BamHI sites of pETllcGST (25) . pET11cGST-VP16&AD (formerly -VP16AC) was a gift from J.-S. Lai (25) ; pET11cGST-STOP, carrying an in-frame stop codon immediately after the GST moiety, was kindly provided by M. Tanaka (Cold Spring Harbor Laboratory).
Cell Culture and Transfections. The altered-specificity TBP assay was-performed in transiently transfected HeLa cells exactly as described (6) . Expression of GAL4-fusion proteins was confirmed by electrophoretic mobility shift analysis of transfected cell extracts; equivalent levels of expression of all mutant TBPs were confirmed by Western blot analysis.
"GST-Pulldown" Assays. GST-fusion proteins were expressed in E. coli by use of the T7 expression system of Studier et al. (26) and bound to glutathione-agarose (Sigma) as described (6) . After extensive washing in HEMGN buffer (2) Abbreviations: TBP, TATA box-binding protein; TAF, TBP-associated factor; GST, glutathione-S-transferase; DBD, DNA-binding domain.
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35S-labeled wild-type and mutant human TBPAS molecules were generated by in vitro transcription and translation with either the TNT coupled transcription/translation system (Promega) or the standard reticulocyte lysate translation system (Promega). The synthesis of full-length TBP was quantitated by SDS/PAGE followed by phosphor imaging (Fuji).
GST 
RESULTS
To probe the functional significance of activator-TBP association, we examined the effects of double and triple alaninesubstitution mutations in TBP on both association with activators in vitro and response to activators in vivo. The TBP structure, shown in Fig. 1 (30) . We fused these two regions of VP16 individually to GST sequences and examined their ability to bind radiolabeled TBP molecules in a GST- pulldown assay. We also fused the VP16 sequences to the heterologous GAL4 DNA-binding domain (DBD; residues 1-94; ref. 31 ) and determined their potential to activate transcription in vivo from a c-fos reporter construct carrying four synthetic GAL4 binding sites (6) . To 2 and 14) . A GAL4-VP16&AD-fusion protein has previously been shown to activate transcription weakly in mammalian cells (33) ; the difference in activity of our GAL4-VP16&AD protein may reflect the smaller region of GAL4 (residues 1-94 versus 1-147) used in our study.
Whichever the reason, the inactivity of GAL4-VP16&AD described here shows that the ability of VP16AAD to associate with TBP in vitro is not sufficient to achieve transcriptional activation in vivo.
A Double Amino Acid Substitution in TBP That Disrupts Association with the VP16 Activation Domain in Vitro Does Not Affect the Response of TBP to VP16 Activation in Vivo. We next examined the ability of the double and triple alanine substitution mutations on the surface of TBP (Fig. 1) to interfere with the association between TBP and VP16 in vitro.
As previously described (6) , and shown for comparison in Fig.  2B , these mutations have little if any effect on c-fos promoter activation in response to GAL4-VP16AD in vivo (lanes 14-18); nor, as expected, do they elicit a response to the transcriptionally inactive GAL4 DBD (lanes 2-6) or GAL4-VP16AAD proteins (lanes 8-12) .
None of these mutations disrupted the in vitro association of TBPAS with GST-VP16&AD ( Fig. 2A, lanes 12-15) . Similarly, three of the mutations-Hi', H2, and 53/54-as well as alanine substitutions in helices Hi and H2' ( Fig. 1 ; data not shown) had no more than a 2-fold effect on the association of TBP with GST-VP16AD (lanes 17-19) . In contrast, however, the S3'/S4' mutation in TBPAS (or wild-type TBP; data not shown) resulted in less than 5% the wild-type level of association with the VP16 activation domain ( Fig. 2A This analysis is shown in Fig. 3 . Like the S3'/S4' mutation, the individual K297A and R299A mutations had little impact on the in vivo response of TBP to GAL4-VP16AD (Fig. 3B, lanes 4 and 5) . Both mutations did, however, have a significant effect on association with the VP16 activation domain in vitro (Fig. 3A) : The K297A mutation reduced the TBP-VP16ADassociation to approximately 12% of wild-type levels (lane 3), and the R299A mutation (lane 4) reduced the association to about 30% of wild-type levels. Thus the in vitro association of TBP with the VP16 activation domain is sensitive to either of two point mutations in a single loop of TBP.
We next engineered these mutations into the H1'+S3/S4 mutant TBP background. Combining the Hl' and S3/S4 mutations resulted in a reduction in TBP-VP16AD association to 30% (Fig. 3A, lane 5) ; this level was reduced to approximately 10% by addition of either the K297A or R299A single mutations (lanes 7 and 8) . In contrast, addition of the K297A and R299A mutations to the H1 '+S3/S4 background had no evident effect on response to GAL4-VP16AD (Fig. 4B, 1-6) or combined (7-13) sets of mutations in TBPAS on response to GAL4-p53AD. GAL4-p53AD is present in all lanes. The positions of correctly initiated c-fos and a-globin transcripts are indicated. H1'+S3/S4 mutations, resulting in the Hi'+S3/S4+S3'/S4' combination, that a significant reduction in GAL4-VP16AD transactivation was observed (lane 7). The finding that both mutations in the S3'/S4' loop are required for disruption of VP16 activation in vivo, whereas each mutation separately is sufficient to disrupt VP16AD association in vitro, argues that disruption of the VP16AD-TBP association does not contribute to the activator-specific transcriptional defects of the Hi' +S3/ S4+S3'/S4' mutation. The S3'/S4' Mutation Also Disrupts Association of TBP with the Activation Domain of p53 in Vitro but Does Not Affect Response to p53 in Vivo. We next examined the functional significance of association between TBP and the acidic activation domain from the human tumor suppressor protein p53 (pS3AD: residues 1-73; ref. 34 ). We fused the p53 activation domain to both GST and GAL4 sequences and then compared association with TBP in vitro with activation in vivo, as shown in Fig. 4 . Consistent with previous reports (34) (35) (36) (37) , the p53 activation domain both bound wild-type TBPAS in vitro (Fig.   4A , lane 1) and activated transcription to high levels in vivo (Fig. 4B, lane 2) . Like transcriptional activation by all activators examined (6), activation by GAL4-p53AD was not significantly affected by any of the single sets of mutations in TBP (Fig. 4B, lanes 3-6) . This pattern was not true of TBP association in vitro, however, because the S3'/S4' mutation (Fig. 4A, lane 5) disrupted binding of TBPAs to GST-p53AD.
The same mutation in TBP therefore disrupts association with both the VP16 and p53 activation domains, suggesting that these two activation domains interact with TBP through similar interfaces. Moreover, the TBP-p53AD association can be disrupted without having an impact on transcriptional activation in vivo, demonstrating that the ability of the p53 activation domain to interact directly with TBP in vitro is not required for transcriptional activation in vivo.
To contrast the activity of the acidic p53 activation domain with that of VP16, we examined the response of several multiply mutant forms of TBP to GAL4-pS3AD in vivo. As observed with all activators (6) , combining the H2 and S3'/S4' mutations reduced response to GAL4-pS3AD in vivo to 10% of wild-type levels (Fig. 4B, compare lanes 8 and 9) . All other double-mutant TBP molecules, regardless of whether they carried the S3'/S4' mutation, were reduced to 50% for response to GAL4-p53AD (compare lane 8 with lanes 10-12) . Remarkably, however, the HI' +S3/S4+S3'/S4' combination, which is reduced to approximately 10% for response to GAL4-VP16AD (Fig. 3) , showed only the same reduction to 50% for response to GAL4-p53AD (Fig. 4B, lane 13) . This result demonstrates that VP16 and p53, two acidic activators which display many structural and functional similarities-including potency of transactivation, association with TFIIH in vitro (13) , association with TBP in vitro, and sensitivity to the S3'/S4' mutation-use TBP in different ways to achieve transcriptional activation in vivo.
DISCUSSION
We have investigated the importance of activator-TBP association in vitro for transcriptional activation in vivo. We found that not only the VP16 activation domain but also the remainder of the protein-which does not activate transcription effectively in vivo-associates well with TBP in vitro. We also found that mutations in a single loop of TBP disrupt its association with the activation domains of VP16 and p53 but do not affect its ability to support activated transcription in vivo. These findings raise the possibility that direct contact of TBP by these activation domains, and perhaps others, is not involved in the transcriptional activation process in vivo.
There promoter recognition (i.e., through the TATA box) but also was a direct target for transcriptional activators. Subsequently, gene duplication may have allowed some TBP functions (e.g., direct activator interaction) to be performed by separate basal factors, which interact with activators but do not recognize promoters directly. Through evolution, therefore, TBP may no longer be generally a direct target of transcriptional activators, but instead has become incorporated into multiprotein complexes such as TFIID (39) in which TAFs are the direct targets.
We suggest that it is the interaction between TBP and the largest human TAF, hTAF11250, that both preserves the ability of TBP to interact with activation domains in vitro and blocks the direct activator-TBP interaction in vivo. TBP interacts with hTAF11250 at multiple points across its surface, including the S3'/S4' loop (6) . The S3'/S4' mutation alone, however, is not sufficient to disrupt either the TBP-hTAF,1250 interaction in vitro or transcriptional activation in vivo; disruption of both these activities requires additional mutations in other regions of TBP (6) . The structure of the S3'/S4' loop of TBP may thus be conserved not for interaction with activators but rather for interaction with factors such as hTAF11250, which subsequently blocks activators from interacting directly with TBP by masking the S3'/S4' loop. In summary, the idea that a common structural motif in basal factors is involved in the protein-protein interactions that regulate transcription provides an explanation of why so many transcription factors can interact directly with TBP and with other basal factors as well. Additionally, the model reinforces the importance of examining activator-basal factor interactions from the point of view of both partners. If common or related motifs are used in activator-target interactions, then examination of the effects of mutations only in activation domains is not sufficient to determine which of the multitude of interactions demonstrated in vitro are directly relevant to transcriptional activation in vivo.
